{"url_path":"/sec/ndra/8-k/2026-06-26/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 ****Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/1681682/0001213900-26-072268-index.html","accession_number":"0001213900-26-072268","cik":"0001681682","ticker":"NDRA","issuer_name":"ENDRA Life Sciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1681682/0001213900-26-072268-index.html","primary_entity_key":"0001681682","primary_entity_name":"ENDRA Life Sciences Inc."},"word_count":134,"has_tables":true,"body_markdown":"**Item 7.01.****Regulation FD Disclosure.**\n\n \n\nFurnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated\nherein by reference is an investor presentation prepared by Renergen in connection with the Noble Investment and that may be used by ASPI,\nRenergen, Noble or ENDRA in connection with the Merger.\n\n \n\nThe information in this Item 7.01, including Exhibit 99.1 attached\nhereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange\nAct”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference in any\nfiling of ENDRA under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall\nbe expressly set forth by specific reference in such filing."}